The incidence rate continues to decline in Spain. This Wednesday, the data is 173 cases per 100,000 inhabitants in the last 14 days, which represents a fall of seven points compared to yesterday’s 180.69. The data rises in the Canary Islands and Extremadura.
Ten autonomous regions have an incidence above the national average: Euskadi (371.54), Madrid (277.19), Aragón (269.60), Melilla (266.43), Navarra (247.58), La Rioja (213.49), Catalonia (212.39), Cantabria (184.08), Castilla-La Mancha (181.59) and Andalusia (174.59).
In addition, this day, the Ministry of Health has registered 6,418 new cases of coronavirus, of which 3,210 have been detected in the last 24 hours. Compared to this Wednesday, the figure is an increase, since then they were 4,941. In total, since the beginning of the pandemic, 3,592,751 people confirmed by test have been infected in Spain.
By communities, Madrid is the one with the most cases (1,500), followed by Catalonia (1,479), Andalusia (1,289) and the Basque Country (503). On the other hand, those that report the least infections are Ceuta (which has not added any), Melilla (21) and the Balearic Islands (40).
Regarding the deceased, the authorities have added 108 new ones, which brings the deaths for more than a year to 79,208: 261 of them have occurred in the last seven days.
In hospitals, as of this Friday there are 7,696 people admitted – 6.13% occupancy -, of which 1,991 need treatment in intensive care units. This means that 20.11% of the places in these ICUs are occupied only by patients with this pathology. Currently there is no community with ICUs above 40%, although Madrid has 39.50%. Behind it, and still above 30%, are Euskadi (33.05%), La Rioja (32.08%), Catalonia (30.83%) and Aragon (30.43%).
This Wednesday, the European Medicines Agency (EMA) has again insisted on what he said three weeks ago about AstraZeneca: “There is no indication that there are problems with a second dose. We continue to recommend that it be applied.”. In Spain, however, it is still weighing what to do, since vaccination to that segment of the population stopped due to sporadic side effects with rare cases of thrombi.
Alternatives include substituting the second dose of AstraZeneca for an mRNA vaccine – Pfizer or Moderna. “But data is lacking,” says the EMA: “We are awaiting the results of a study in the UK in this regard to reach some conclusion. Currently, this body is analyzing four vaccines for future authorization: Curevac, Novavax, Russian Sputnik V and Chinese Sinovac.